News | Computed Tomography (CT) | November 24, 2015

Subsolid Lung Nodules Pose Greater Cancer Risk to Women Than Men

Data show women 50 percent more likely than men to have ground-glass, or hazy, lung nodules on CT screening

subsolid lung nodules, lung cancer, CT screening, women and men, NLST

November 24, 2015 — Women with a certain type of lung nodule visible on lung cancer screening computed tomography (CT) exams face higher lung cancer risk than men with similar nodules, according to a study being presented at the annual meeting of the Radiological Society of North America (RSNA).

Lung nodules are small masses of tissue in the lungs that are classified as solid or subsolid based on their appearance on CT. Solid nodules are dense, and they obscure adjacent tissue, while subsolid nodules are divided into two different types: part solid (nodules with both a solid component and a ground-glass, or hazy area), and pure ground glass, which are devoid of solid elements. Nodule consistency is considered an indicator of lung cancer risk, with part solid nodules being most strongly associated with lung cancer in the screening setting.

"We know there are differences in cancer risk among different lung nodule consistencies, but we were unaware of any published reports that looked at the differences in lung cancer risk for nodule subtypes between women and men," said study lead author Phillip Boiselle, M.D., from Beth Israel Deaconess Medical Center and Harvard Medical School in Boston.

For the new study, Boiselle and colleagues reviewed CT scans from the National Lung Screening Trial (NLST), a large, randomized control study that demonstrated the value of CT screening in reducing lung cancer mortality. The NLST included more than 40 percent women, giving the research team a rare opportunity to look for statistically significant differences in lung nodules and lung cancer between the sexes.

The researchers characterized all CT-detected nodules measuring 4 to 30 millimeters by consistency using the NLST database and calculated the relative risk of developing a lung cancer for each nodule consistency subtype.

Out of 26,455 participants, 9,994 (37.8 percent) had a positive screen at one or more points during the trial. Women with ground-glass nodules had a significantly higher relative risk of lung cancer than men with the same type of nodules, and a similar trend was observed for part-solid nodules. In contrast, the relative risk of lung cancer for solid nodules was comparable for both sexes.

Part-solid nodules had the highest predictive value of cancer in both sexes, whereas solid nodules had the lowest predictive value in women and ground glass nodules had the lowest predictive value in men.

"The main difference we found was that women were 50 percent more likely than men to have ground-glass nodules and, when these nodules were present, women had a substantially higher risk of developing lung cancer," Boiselle said.

Current lung cancer screening guidelines do not take into account gender differences when managing nodules of different consistencies. While more research is needed before changes are made to clinical practice, the results suggest that women with ground glass nodules may need closer follow-up than men.

"By looking at the rate at which lung cancers grow on serial CT scans, we can develop a better understanding of how often to obtain follow-up CT scans in men and women," Boiselle said.

The researchers plan to continue studying the NLST data to further understand the significance of these cancers, especially with respect to their influence on lung cancer mortality.

Co-authors on the study are Fenghai Duan, Ph.D.; Stavroula Chysanthopoulou, Ph.D.; Sarah DeMello, M.S.; Denise R. Aberle, M.D.; and Caroline Chiles, M.D.

For more information: www.radiologyinfo.org

Related Content

A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning
Technology | Artificial Intelligence | February 15, 2018
February 15, 2018 — Arterys Inc. announced its fifth 510(k) clearance from the U.S.
Sponsored Content | Videos | Imaging | February 15, 2018
David Widmann, president and CEO of Konica Minolta, looks at what the future of healthcare can bring to its customers,...
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
Videos | Enterprise Imaging | February 13, 2018
ITN Contributing Editor Greg Freiherr offers an overview of enterprise imaging advances at the Radiological Society of...
Planmed Launches Improved Planmed Verity CBCT Scanner
Technology | Computed Tomography (CT) | February 07, 2018
Planmed announced the launch of the improved Planmed Verity cone beam computed tomography (CBCT) scanner for orthopedic...
NEST Program Names ACR Data Science Institute AI Use Case as Demonstration Project
News | Artificial Intelligence | February 07, 2018
A U.S. Food and Drug Administration (FDA)-funded program to speed safe and effective medical device technologies to...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
MedyMatch Receives FDA Device Designation for Intracranial Hemorrhage Software
News | Computed Tomography (CT) | February 01, 2018
February 1, 2018 – MedyMatch Technology, a company focused on helping physicians provide accurate patient assessment
Overlay Init